Isolated limb infusion for malignant melanoma: Predictors of response and outcome

Annals of Surgical Oncology

Volumn 16, Issue 12, 2009, Pages 3463-3472

  Barbour, Andrew P ^a   Thomas, Janine ^a   Suffolk, Jennifer ^a   Beller, Elaine ^a   Smithers, B Mark ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; DEEP VEIN THROMBOSIS; DIATHERMY; DRUG ADMINISTRATION ROUTE; EDEMA; ERYTHEMA; FEMALE; HEMATOMA; HUMAN; HYPERTHERMIC THERAPY; INOPERABLE CANCER; ISOLATED LIMB INFUSION; LASER SURGERY; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PAIN; PROGNOSIS; ULCER;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 71549118535     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0717-9     Document Type: Article

References (34)

1. BB Kroon EM Noorda BC Vrouenraets OE Nieweg 2002 Isolated limb perfusion for melanoma J Surg Oncol 79 4 252 255 10.1002/jso.10077 11920783 (Pubitemid 34259819)
2. P Lindner A Doubrovsky PC Kam JF Thompson 2002 Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma Ann Surg Oncol 9 2 127 136 11888868
3. WR Cornett LM McCall RP Petersen, et al. 2006 Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020 J Clin Oncol 24 25 4196 4201 10.1200/JCO.2005.05.5152 1:CAS:528:DC%2BD28XhtVantbvL 16943537 (Pubitemid 46622299)
4. JF Thompson PC Kam RC Waugh CR Harman 1998 Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion Semin Surg Oncol 14 3 238 247 10.1002/(SICI)1098-2388(199804/05)14:3<238::AID-SSU8>3. 0.CO;2-9 1:STN:280:DyaK1c3gvVertQ%3D%3D 9548607 (Pubitemid 28146516)
5. HM Kroon M Moncrieff PC Kam JF Thompson 2008 Outcomes following isolated limb infusion for melanoma. A 14-year experience Ann Surg Oncol 15 11 3003 3013 10.1245/s10434-008-9954-6 18509706
6. R Mian MA Henderson D Speakman, et al. 2001 Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion Can J Surg 44 3 189 192 1:STN:280:DC%2BD3MzksVOqtw%3D%3D 11407828
7. MS Brady K Brown A Patel, et al. 2006 A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity Ann Surg Oncol 13 8 1123 1129 10.1245/ASO.2006.05.003 16791448 (Pubitemid 44337972)
8. GM Beasley RP Petersen J Yoo, et al. 2008 Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion Ann Surg Oncol 15 8 2195 2205 10.1245/s10434-008-9988-9 18528730
9. ER Ryan AD Hill SJ Skehan 2006 FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma Clin Nucl Med 31 11 707 708 10.1097/01.rlu.0000242602.56590.c5 17053391 (Pubitemid 44624560)
10. DL Fraker 2004 Management of in-transit melanoma of the extremity with isolated limb perfusion Curr Treat Options Oncol 5 3 173 184 10.1007/s11864-004-0009-3 15115646
11. Kam PC, Thompson JF. Pharmacokinetics of regional therapy: isolated limb infusion and other low flow techniques for extremity melanoma. Surg Oncol Clin North Am. 2008;17(4):795-804, ix.
12. J Wieberdink C Benckhuysen RP Braat, et al. 1982 Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions Eur J Cancer Clin Oncol 18 10 905 910 10.1016/0277-5379(82)90235-8 1:STN:280:DyaL3s7jtFOksQ%3D%3D 6891640
13. World Health Organization. Geneva: World Health Organization. WHO Handbook for Reporting Results of Cancer Treatments (WHO Offset Publication No. 48).
14. RSD Miller 1982 Maximally selected chi-square statistics Biometrics 38 1011 1016 10.2307/2529881
15. TA Aloia E Grubbs M Onaitis, et al. 2005 Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response Arch Surg 140 11 1115 1120 10.1001/archsurg.140.11.1115 16301451 (Pubitemid 41668683)
16. DR Minor RE Allen D Alberts, et al. 1985 A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma Cancer 55 11 2638 2644 10.1002/1097-0142(19850601)55:11<2638::AID-CNCR2820551118>3. 0.CO;2-E 1:STN:280:DyaL2M3gtFentw%3D%3D 3995475 (Pubitemid 15092151)
17. F Di Filippo A Calabro D Giannarelli, et al. 1989 Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion Cancer 63 12 2551 2561 10.1002/1097-0142(19890615)63:12<2551::AID- CNCR2820631233>3.0.CO;2-7 1:STN:280:DyaL1M3kvVyltQ%3D%3D 2720604 (Pubitemid 19152772)
18. JM Klaase BB Kroon AN van Geel, et al. 1994 Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan Surgery 115 1 39 45 1:STN:280:DyaK2c7ht1Kmtw%3D%3D 8284759
19. AI Skene AS Bulman TR Williams, et al. 1990 Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb Br J Surg 77 7 765 767 10.1002/bjs.1800770716 1:STN:280: DyaK3czksFWktw%3D%3D 2383752 (Pubitemid 20236115)
20. GM Beasley A Caudle RP Petersen, et al. 2009 A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US J Am Coll Surg 208 5 706 715 10.1016/j.jamcollsurg.2008.12.019 19476821 discussion 715-7
21. OI Abdel-Wahab E Grubbs BL Viglianti, et al. 2004 The role of hyperthermia in regional alkylating agent chemotherapy Clin Cancer Res 10 17 5919 5929 10.1158/1078-0432.CCR-04-0096 1:CAS:528:DC%2BD2cXntlyjt7s%3D 15355925 (Pubitemid 39180974)
22. DW Siemann M Chapman A Beikirch 1991 Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy Int J Radiat Oncol Biol Phys 20 2 287 289 1:STN:280:DyaK3M7itlWhuw%3D%3D 1991690
23. JM Klaase BB Kroon JH Beijnen, et al. 1994 Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb Br J Cancer 70 1 151 153 1:STN:280:DyaK2c3ovFalsw%3D%3D 8018528
24. TG Zogakis DL Bartlett SK Libutti, et al. 2001 Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma Ann Surg Oncol 8 10 771 778 10.1007/s10434-001-0771-4 1:STN:280:DC%2BD38%2FkvVynsg%3D%3D 11776490
25. A Sanki PC Kam JF Thompson 2007 Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology Ann Surg 245 4 591 596 10.1097/01.sla.0000251746.02764.fc 17414608 (Pubitemid 46555663)
26. EM Noorda BC Vrouenraets OE Nieweg, et al. 2006 Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion Eur J Surg Oncol 32 3 318 324 10.1016/j.ejso.2005.10.009 1:STN:280:DC%2BD287lvF2muw%3D%3D 16412605
27. FJ Lejeune D Lienard S Leyvraz RO Mirimanoff 1993 Regional therapy of melanoma Eur J Cancer 29A 4 606 612 10.1016/S0959-8049(05)80163-7 1:STN:280:DyaK3s7mvVClsA%3D%3D 8435217
28. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. 2009: ahead of print.
29. CM Balch AC Buzaid SJ Soong, et al. 2001 Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 16 3635 3648 1:STN:280:DC%2BD3MvlvV2ktQ%3D%3D 11504745
30. Kroon BB, Noorda EM, Vrouenraets BC, et al. Isolated limb perfusion for melanoma. Surg Oncol Clin North Am. 2008;17(4):785-94, viii-ix.
31. DP Jaques DG Coit MF Brennan 1989 Major amputation for advanced malignant melanoma Surg Gynecol Obstet 169 1 1 6 1:STN:280:DyaL1M3pvVGksA%3D%3D 2472674
32. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009 [Ahead of print]
33. N McMahon TY Cheng GM Beasley, et al. 2009 Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 16 4 953 961 10.1245/s10434-008-0288-1 1:STN:280:DC%2BD1M7ptFKrsg%3D%3D 19184236
34. JF Thompson GA Siebert YG Anissimov, et al. 2001 Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies Br J Cancer 85 2 157 165 10.1054/bjoc.2001.1902 1:CAS:528:DC%2BD3MXmtVKhsL0%3D 11461070 (Pubitemid 32700296)